BusinessHemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue SyndromeBy Nasdaq OMXAug 8, 2017, 10:08 AM UTC
BusinessHemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue SyndromeBy Nasdaq OMXAug 4, 2017, 12:30 PM UTC
BusinessHemispherx Biopharma Enhances Ampligen Manufacturing and Scientific CapabilitiesBy Nasdaq OMXMay 31, 2017, 3:40 PM UTC
BusinessHemispherx Biopharma Enhances Ampligen Manufacturing and Scientific CapabilitiesBy Nasdaq OMXMay 31, 2017, 3:40 PM UTC
BusinessHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine RepublicBy Nasdaq OMXAug 26, 2016, 12:30 AM UTC
BusinessHemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)By Nasdaq OMXMar 10, 2016, 1:30 PM UTC
